Colonization of nasal cavities by *Staphylococcus epidermidis* mitigates SARS-CoV-2 nucleocapsid phosphoprotein-induced interleukin (IL)-6 in the lung

Ming-Shan Kao,¹ Jen-Ho Yang,¹† Arun Balasubramaniam,¹,† Supitchaya Traisaeng,² Albert Jackson Yang,¹ John Jackson Yang,¹ Benjamin Prethiviraj Salamon,¹ Deron R. Herr³ and Chun-Ming Huang¹,⁴

¹Department of Biomedical Sciences and Engineering, National Central University, Taoyuan, 3201, Taiwan.  
²Department of Life Sciences, National Central University, Taoyuan, 3201, Taiwan.  
³Department of Biology, San Diego State University, San Diego, CA 92182, USA.  
⁴Department of Biomedical Science and Environment Biology, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.

**Summary**

Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can trigger excessive interleukin (IL)-6 signalling, leading to a myriad of biological effects including a cytokine storm that contributes to multiple organ failure in severe coronavirus disease 2019 (COVID-19). Using a mouse model, we demonstrated that nasal inoculation of nucleocapsid phosphoprotein (NPP) of SARS-CoV-2 increased IL-6 content in bronchoalveolar lavage fluid (BALF). Nasal administration of liquid coco-caprylate/caprate (LCC) onto *Staphylococcus epidermidis* (*S. epidermidis*)-colonized mice significantly attenuated NPP-induced IL-6. Furthermore, *S. epidermidis*-mediated LCC fermentation to generate electricity and butyric acid that promoted bacterial colonization and activated free fatty acid receptor 2 (Ffar2) respectively. Inhibition of Ffar2 impeded the effect of *S. epidermidis* plus LCC on the reduction of NPP-induced IL-6. Collectively, these results suggest that nasal *S. epidermidis* is part of the first line of defence in ameliorating a cytokine storm induced by airway infection of SARS-CoV-2.

**Introduction**

Severe coronavirus disease 2019 (COVID-19)-associated pneumonia patients develop features of systemic hyper-inflammation under the umbrella terms of ‘macrophage activation syndrome’ or ‘cytokine storm’ (McGonagle *et al*., 2020). Pro-inflammatory cytokines, especially interleukin (IL)-6, are highly elevated in severely ill COVID-19 patients (Chen *et al*., 2020; Huang *et al*., 2020a; Qin *et al*., 2020; Tan *et al*., 2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) selectively induces IL-6 production and results in the exhaustion of lymphocytes (Tang *et al*., 2020). It has been documented that the nucleocapsid phosphoprotein (NPP) of SARS-CoV-2 is essential for viral activation of IL-6 gene induction (Zhang *et al*., 2007). Furthermore, NPP of SARS-CoV can directly bind to nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) response elements and can activate IL-6 expression by facilitating the translocation of NF-κB from cytosol to nucleus (Zhang *et al*., 2007).

*Staphylococcus epidermidis* (*S. epidermidis*) is a Gram-positive bacterium that is an abundant component of the microbiome of the human nasal mucosa and the respiratory tract. Several studies provide evidence for a protective role of nasal *S. epidermidis* in the defence against viral infection. For instance, the extracellular matrix-binding protein (Embp) of *S. epidermidis* can bind directly to influenza virus (Chen *et al*., 2016) and intranasal inoculation of Embp induces the expression of antiviral cytokines in the nasal tissues. In addition, exposure of nasal epithelia cells to nasal-derived *S. epidermidis* was shown to increase expression and release of interferon (IFN)-α in response to influenza virus exposure (Kim *et al*., 2019). Data from our laboratory has revealed probiotic activity of *S. epidermidis*, which can metabolize carbon-rich molecules such as glycerol to yield short-chain fatty acids (SCFAs) (Keshari *et al*., 2019; Traisaeng *et al*., 2019) and electrons (Balasubramaniam...
**S. epidermidis** that (Kao et al., 2022) has recently identified (Kao et al., 2017). Cumulatively, these studies suggest that **S. epidermidis** in the nasal microbiome may act as a front-line defender against virus infection. Suppression of early-stage viral infection by nasal bacteria may reduce nasal invasion of SARS-CoV-2 and minimize airborne transmission of COVID-19.

The challenges in developing an effective COVID-19 vaccine included antigenic drift and increased risk of adverse effects due to fast-tracked development. Furthermore, the cases of COVID-19 reinfection have been recently identified (Lu et al., 2020), raising concerns regarding the durability of vaccine-induced responses and the efficacy of this approach in developing herd immunity. Also, the low effectiveness against SARS-CoV-2 variants among COVID-19 vaccinated persons has been reported (Dong et al., 2020; Levine-Tiefenbrun et al., 2021). Antiviral drugs, such as remdesivir, have shown some promise in initial clinical trials, but may be ineffective if administered late in COVID-19 progression. The use of nasal bacteria may offer a valuable therapeutic approach to combat SARS-CoV-2, in place of or in addition to vaccines and antiviral drugs. Such bacteria are natural inhabitants of the upper respiratory tract, their action does not require full host immune stimulation, and they can hinder viral entry at the early stages of infection. We evaluated this effect *in vivo* by applying liquid coco-caprylate/caprate (LCC) to the nasal cavities of mice to trigger fermentation of resident **S. epidermidis**. LCC, a Food and Drug Administration (FDA)-approved compound with C8-10 fatty acid connected to C12-C18 fatty alcohols, is currently used as a topical emollient to minimize ultraviolet (UV) radiation exposure (Sohn et al., 2020). Our results identify the novel biological function of **S. epidermidis** as a nasal commensal bacterium capable of protecting against SARS-CoV-2. We further provide evidence for the potential value of LCC as a repurposed or repositioned drug (Beigel et al., 2020; Tomazini et al., 2020) against COVID-19.

**Results**

**Nasal inoculation of NPP of SARS-CoV-2 in mice induces an increase in IL-6 in the lung**

The gene-encoding NPP [protein identification (ID): YP_009724397.2] of SARS-CoV-2 was transformed into *Escherichia coli* (E. coli) BL21 competent cells. After isopropyl β-D-thiogalactopyranoside (IPTG) induction and purification, recombinant NPP with an apparent molecular mass of approximately 48 kDa determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was obtained. Expression of recombinant green fluorescent protein (GFP) in *E. coli* BL21 competent cells was conducted by following the same procedure. IL-6 plays a central role in both innate and adaptive immunities and is a key component of the cytokine storm during the progression of COVID-19. Up-regulation of IL-6 can be induced by infection of many viruses including SARS-CoV (Wang et al., 2007). To examine whether NPP of SARS-CoV-2 can regulate the IL-6 production, we intranasally inoculated recombinant NPP or control GFP into Institute of Cancer Research (ICR) mice for 6 h. The level (273.90 ± 8.86 pg ml⁻¹) of IL-6 in bronchoalveolar lavage fluid (BALF) collected from NPP-inoculated mice was approximately 10-fold higher than that (25.03 ± 4.98 pg ml⁻¹) in BALF collected from GFP-inoculated mice (Fig. 1A). This result demonstrates for the first time that NPP of SARS-CoV-2 is sufficient to up-regulate IL-6 in the lung and supported the previous finding that NPP of other coronavirus can activate IL-6 gene expression by binding directly to NF-κB regulatory element on IL-6 promoter (Zhang et al., 2007).

**LCC fermentation mediates electricity production that is essential for nasal colonization of S. epidermidis**

Data from our previous analysis have revealed that **S. epidermidis** fermentatively metabolizes glycerol (C₃H₈O₃) as a carbon source to yield electricity (Balasubramaniam et al., 2020). The process of generating electrons in **S. epidermidis** mitigates SARS-CoV-2-induced IL-6.

---

**Fig. 1.** Nasal inoculation of recombinant NPP increased IL-6 in BALF in mice (A) Recombinant NPP or GFP was inoculated into the nasal cavities of ICR mice for 6 h. The levels of IL-6 in BALF were measured by ELISA. The level of IL-6 induced by recombinant NPP was expressed as fold change over that induced by recombinant GFP. The *P*-value of < 0.001 (***) from three different experiments with mean ± SD was shown.
was similar to flavin-based extracellular electron transfer (EET) in other Gram-positive bacteria (Light et al., 2018). Riboflavin kinase (EC 2.7.1.26) is a key enzyme that catalyses the synthesis of flavin mononucleotide (FMN) from riboflavin (Sebastian et al., 2019). Roseofoflavin, as an inhibitor of riboflavin kinase, can block bacterial riboflavin riboswitches (Miroix and Walker, 1996; Mansjö and Johansson, 2011). Here, S. epidermidis without pretreatment of roseofoflavin was placed on the anode of a digital multimetre in the presence of LCC with a longer carbon chain (C8-10 fatty acid connected to C12-C18 fatty alcohols). As shown in Fig. 2A, a significant increase in voltage with a peak value of approximately 6 mV was observed throughout the 20 min monitoring period when media contained S. epidermidis plus LCC. The voltage change provoked by S. epidermidis in the presence of LCC was completely attenuated when S. epidermidis was pretreated with roseofoflavin, indicating that riboflavin kinase was involved in flavin-based EET in electrogenic S. epidermidis.

The bacterial EET system involves bacterial communication and attachment architecturally complex microbial communities such as biofilm (Patil et al., 2012; Sarjit et al., 2015). We thus evaluated whether electricity produced by S. epidermidis plus LCC influences the bacterial nasal colonization, S. epidermidis pretreated with or without roseofoflavin was intranasally inoculated onto mice every day for three days. Bacterial residence in the nasal cavity was quantified by culturing limiting dilutions of tissue homogenates on streptomycin-supplemented tryptic soy broth (TSB) agar plates. Results demonstrated that only inoculated S. epidermidis, but not endogenous bacteria, can grow colonies on streptomycin supplemented TSB agar plates (Fig. S1). By counting bacterial colony forming unit (CFU) in nasal homogenates after three days of inoculation, we found that the S. epidermidis content in mice pretreated with roseofoflavin (1.50 ± 0.20 × 10⁴ CFU g⁻¹) was approximately half that of mice that did not receive roseofoflavin pretreatment (3.16 ± 0.49 × 10⁴ CFU g⁻¹) (Fig. 2B). These results suggest that riboflavin kinase-mediated electricity production of S. epidermidis may affect bacterial colonization of the nasal sinus.

Produced of butyric acid by S. epidermidis-colonized nasal septum

S. epidermidis can mediate fermentation to produce SCFAs. Butyric acid, one of SCFAs, functions as an electron donor (Finke et al., 2007) and has been shown to exert potent anti-inflammatory effects (Keshari et al., 2020). To investigate if S. epidermidis can metabolize LCC to produce butyric acid, the nasal septa isolated from ICR mice were topically applied with S. epidermidis in the presence of 2% LCC and incubated in rich media for 24 h. Incubation of nasal septa with S. epidermidis in

Fig. 2. Bacterial electricity and nasal colonized were reduced by pretreatment of S. epidermidis with roseofoflavin (A) Electricity indicated by voltage changes (mV) was detected in the LCC culture of S. epidermidis pretreated with/without roseofoflavin. (B) Nasal cavities of ICR mice were inoculated daily with S. epidermidis pretreated with/without roseofoflavin for 3 days. The number (CFU g⁻¹) of S. epidermidis on nasal cavities were counted by plating serial dilutions (1:10⁻¹–1:10⁵) of nasal homogenates on a streptomycin supplemented TSB agar plate. Bacterial CFU per gram (CFU g⁻¹) of excised nasal cavities was calculated. Data are represented as mean ± SD with the P-value of < 0.01 (**) from experiments in triplicate. Five mice per group were evaluated.
the absence of LCC served as a control. High-performance liquid chromatography (HPLC) analysis was conducted to quantify the level of butyric acid in media of bacteria. The concentration of butyric acid in media conditioned by LCC-treated bacteria on nasal septa was markedly higher than that in media from control cultures (Fig. 3). The different concentrations of butyric acid (0–100 mM) were subjected to HPLC to establish a quantitative standard curve. As shown in Fig. 3B, LCC fermentation of *S. epidermidis* on nasal septum for 24 h yielded approximately 5.87 mM of butyric acid.

*S. epidermidis* plus LCC attenuates NPP-induced IL-6 production in BALF via activation of free fatty acid receptor 2 (Ffar2)

To assess whether butyric acid (Fig. 3) and electron (Fig. 2) production can regulate NPP-induced IL-6, LCC or phosphate-buffered saline (PBS) (control) were intra-nasally administered into the mice nasally colonized with *S. epidermidis* K1, a strain isolated from human nasal cavities (Table S1) before inoculation with recombinant NPP. The level of IL-6 in BALF was quantified by sandwich enzyme-linked immunosorbent assay (ELISA) 6 h after NPP inoculation. Compared with PBS control, the administration of LCC significantly reduced NPP-induced IL-6 in BALF (Fig. 4A). Administration of LCC into nasal cavities of mice without *S. epidermidis* colonization did not alter the level of IL-6 in BALF compared with administration of water (Fig. S2). These results indicated that LCC alone had no effect on reduction of IL-6 induced by NPP, but rather, is likely to be metabolized by *S. epidermidis* fermentation into anti-inflammatory butyric acid.

Ffar2, also known as G protein-coupled receptor 43 (GPR43), is expressed by various cells including macrophages and epithelial cells in nasal cavities and lung (Wang et al., 2020). Butyric acid is a potent (micromolar) agonist of Ffar2. To validate the contribution of Ffar2 to the effect of butyric acid-producing *S. epidermidis* on lowering NPP-induced IL-6, GLPG-0974 was given to *S. epidermidis*-colonized mice to antagonize the Ffar2 before administration of LCC. Compared with IL-6 content (132.0 ± 56.54 pg ml⁻¹) in mice treated with vehicle, treatment with GLPG-0974 resulted in a nearly 3-fold increase in the level (442.0 ± 69.95 pg ml⁻¹) of IL-6 in BALF (Fig. 4B). In the macrophage culture experiment, IL-6 level also increased 2 times after treated with GLPG-0974 in the media containing butyric acid (Fig. S3). Taken together, these data demonstrate that LCC fermentation of nasal *S. epidermidis* requires Ffar2.

![Fig. 3. LCC induced production of butyric acid of *S. epidermidis* colonized on nasal septum (A) The epithelial layer of isolated nasal septum was placed with *S. epidermidis* with or without LCC in rich media for 24 h. Representative chromatograms of HPLC analysis of butyric acid in media were shown. (B) The concentration (mM) of butyric acid was quantified based on the heights [milli-absorbance unit (mAU)] of standard (STD) peaks with concentrations of butyric acid from 0-100 mM. Data are represented as mean ± SD. The *P*-value of < 0.001 (***+) was obtained from three different experiments.](image-url)
Although both NPP and GFP purified from E. coli BL21 may contain lipopolysaccharide (LPS), the secretion of IL-6 induced by NPP was approximately 10-fold higher than that induced by GFP (Fig. 1A), demonstrating that the IL-6 secretion is mainly triggered by NPP, not LPS.

LCC is an ester synthesized from the reaction of the coconut alcohol-derived fatty acids with a mixture of caprylic acid and capric acid (Fiume et al., 2015). Literature has reported that caprylic acid or capric acid exert anti-inflammatory activity via down-regulation of NF-κB (Huang et al., 2014; Zhang et al., 2019). However, our results indicate that nasal administration of LCC did not directly affect NPP-induced IL-6 in BALF (Fig. S2). One possible explanation is that LCC, as a complex of medium chain fatty acids, may need to be catabolized before entering cells to down-regulate the NF-κB. We show that S. epidermidis can fermentatively metabolize LCC to butyric acid and yield electricity (Figs. 2 and 3). Butyric acid can inhibit histone deacetylase to reduce lung inflammation by regulating the Toll-like receptor/NF-κB signalling pathway (Liu et al., 2019). We further show that reduction of NPP-induced IL-6 in BALF by nasal administration of LCC onto S. epidermidis colonized mice is mediated by Ffar2 (Fig. 4), since S. epidermidis colonized mice orally given GLPG-0974, a Ffar2 antagonist, retained elevated levels of NPP-induced IL-6 in BALF after nasal administration of LCC. A pharmacokinetic and pharmacodynamic study revealed that GLPG-0974 was detectable in the blood and inactivated Ffar2 of neutrophils in the blood (Namour et al., 2016). Thus, when mice were given GLPG-0974 via oral gavage, GLPG-0974 can be delivered to the upper respiratory tract to inhibit Ffar2 expressed by immune cells and epithelia cells of nose and lung. It has been shown that SCFAs can activate Ffar2 to ameliorate inflammation initiated by NF-κB signalling (Huang et al., 2020b). Thus, we envision that S. epidermidis-colonized nasal cavities can convert LCC to butyric acid and electrons. Butyric

**Discussion**

Previous studies have revealed that NPP (Sequence ID: AAR12990.1) of SARS-CoV (SARS coronavirus HB) can bind directly to the NF-κB recognition elements on the IL-6 promoter and regulate IL-6 expression (Zhang et al., 2007). The region from amino acids 86 to 96 (GYYRRATRRAR) at the N terminus of SARS-CoV NPP is essential for the viral protein to activate IL-6 transcription. The NPP of SARS-CoV-2 in this study shares 90% sequence identity to NPP (Sequence ID: AAR12990.1) of SARS-CoV. Furthermore, amino acids 85 to 95 (GYYRRATRRIR) at the N terminus of SARS-CoV-2 NPP differ by only one amino acid compared with SARS-CoV NPP. This amino acid alignment suggests that the increase in IL-6 after nasal inoculation of SARS-CoV-2 NPP (Fig. 1B) may be due to the binding of NPP to NF-κB response elements in cells of the nose and lung. To ensure the purified NPP could trigger the inflammation in the cells, the treatment of macrophage experiment was done and we found purified NPP induced approximately 4 times IL-6 higher than GFP (Fig. S3). The results also supported the utility of targeting the IL-6 pathway for the treatment of COVID-19. Although three neutralizing antibodies that target IL-6 signalling are being evaluated for efficacy as COVID-19 therapeutics (Solis-Garcia Del Pozo et al., 2020), we took an approach of drug repurposing to validate the effect of nasal inoculation of LCC on NPP-induced IL-6. Although both NPP and GFP purified from E. coli BL21 may contain lipopolysaccharide (LPS), the secretion of IL-6 induced by NPP was approximately 10-fold higher for its protective effect in attenuating NPP-induced IL-6 production.

**Fig. 4.** Involvement of Ffar2 in the reduction of NPP-induced IL-6 by inoculation of LCC onto S. epidermidis-colonized mice (A) S. epidermidis-colonized ICR mice were intranasally applied with LCC (+ LCC) or PBS (-LCC) 1 h before inoculation of NPP for 6 h. The level of IL-6 in BALF induced by NPP was expressed as fold change over that induced by PBS. (B) S. epidermidis-colonized ICR mice were given GLPG-0974, a Ffar2 antagonist (+), or vehicle (ethanol) alone (-) by gastric gavage every day for 3 days. After administration of GLPG-0974, mice were intranasally applied with LCC 6 h before inoculation with NPP. The level of IL-6 in BALF of mice given with GLPG-0974 was expressed as fold change over that in BALF of mice given without GLPG-0974. The P-value of < 0.001 (**); < 0.0001 (*** from three independent experiments with mean ± SD is shown.
acid may bind to Ffar2 in cells in the upper respiratory tract to down-regulate NF-κB and IL-6 secretion. Angiotensin-converting enzyme 2 (ACE-2) has been identified as a SARS-CoV-2 receptor (Gilzad-Kohan and Jamali, 2020), and our current work demonstrates that Ffar2 attenuates SARS-CoV-2 pathology. Future work will investigate whether Ffar2 regulates inflammation after SARS-CoV-2 binds to ACE-2.

Bacteria can excrete electron acceptors such as flavin molecules that act as small diffusible shuttle molecules to transfer electrons (Marsili et al., 2008). We show here that inhibition of riboflavin kinase by 1 μM roseoavin markedly attenuates electricity production of *S. epidermidis* plus LCC (Fig. 2A). Although a direct anti-bacterial activity of roseoavin has been reported (Lee et al., 2009), we found that incubation of *S. epidermidis* (10^7 CFU) with roseoavin at concentrations less than 1 μM for 24 h did not affect the formation of bacterial colonies on TSB agar plates (data not shown). Thus, inhibition of bacterial electricity production by pretreatment of *S. epidermidis* with roseoavin may be due to a decrease in the synthesis of flavin molecules, rather than the inhibition of bacterial growth. The different direct electric currents can affect bacterial surface properties and adhesion (Luo et al., 2005). Bacterial aggregation can be promoted by adding electron acceptors (Gomez-Carretero et al., 2017). Furthermore, bacteria can use SCFAs as electron donors and oxygen near the epithelial cells of host as an electron acceptor to generate a proton motive force that sustains efficient motility and growth for bacterial colonization (van der Stel et al., 2017). As shown in Fig. 2, roseoavin-pretreated *S. epidermidis* has significantly lost the ability to yield electricity and colonize nasal cavities of mice. *S. epidermidis* may utilize LCC to produce butyric acid as an electron donor and FMN as an electron acceptor. Oxygen on the surface of nasal epithelial cells also acts as an electron acceptor. The electron transfer between donors (butyric acid) and acceptors (FMN and oxygen) may facilitate bacterial colonization. Roseoavin treatment may reduce the FMN production (Lee et al., 2009) and disrupt electron transfers, leading to poor colonization of *S. epidermidis* on nasal cavities.

To investigate whether wild-type *S. epidermidis* from human nostrils can undergo LCC fermentation as efficiently as *S. epidermidis* ATCC 22228, a non-biofilm forming laboratory (MacLea and Trachtenberg, 2017), nasal swabs were collected from one healthy subject and spread on TSB agar plates. Eleven colonies on TSB agar plates were selected for 16S rRNA sequencing. Seven of eleven colonies were identified as *S. epidermidis* (K1, K2, H1, H2, 2, 4 and 5 strains) with 99.6–100% sequence identity to *S. epidermidis* ATCC 22228 (Table S1). Four colonies were identified as *Bacillus pumilus* (B. pumilus), *Terribacillus goriensis* (T. goriensis), *Kocuria indica* (K. indica) and *Corynebacterium segmentosum* (C. segmentosum). To examine the fermentative capabilities, *S. epidermidis* K1 strain was cultured in rich media in the presence of 2% LCC for 12 h. Rich media with LCC alone or *S. epidermidis* K1 alone served as controls. The media in the culture of *S. epidermidis* K1 with LCC turned yellow after incubation for 12 h, while the media in the other three conditions maintained their original colours (Fig. S4A), indicating that *S. epidermidis* K1 strain has a capability of fermenting LCC. To investigate the bacterial electrogenericity, *S. epidermidis* K1 strain with 2% LCC in rich media was added onto the surface of the anode. Addition of the same volume of media, *S. epidermidis* K1 alone, or 2% LCC alone acted as controls. As shown in Fig. S4B, little or no voltage change was detected in media alone or media containing LCC alone. The approximately 4 mV current detected in rich media containing *S. epidermidis* K1 alone could be because bacteria can utilize dextrose in TSB of rich media as an electron donor. However, a marked increase in voltage to 6 mV was detected when 2% LCC was added to media containing *S. epidermidis* K1. In addition, by performing the quantitative real-time polymerase chain reaction (qPCR), we found that the expression of genes, pyruvate dehydrogenase (pdh) and type II NADH: quinone oxidoreductase (ndh2), related to EET in *S. epidermidis* K1, was higher than that in *S. epidermidis* ATCC 12228 (Fig. S5). These results support that the human nasal *S. epidermidis* K1 can undergo LCC fermentation and produce electricity.

It has been reported that the abundance of *Fusobacterium periodonticum* (F. periodonticum), a bacterium in the human nasopharyngeal microbiome, significantly decreased after SARS-CoV-2 infection (Moore et al., 2020; Nardelli et al., 2021). The sialic acid residues on the surface of *F. periodonticum* worked as alternative receptors of the SARS-CoV-2 spike protein, decreasing the probability of viral binding to human ACE-2 positive nasal epithelial cells, the main target of invasion for SARS-CoV-2 to enter into the human body (Morniroli et al., 2020; Gallo et al., 2021). Previous studies demonstrated that the nasal *S. epidermidis* significantly reduced the expression of ACE-2 gene in host cells (Ji et al., 2021). These results revealed the beneficial effects of nasal commensal bacteria on reduction of SARS-CoV-2 infection.

In summary, immune responses activated by SARS-CoV-2 infection lead to uncontrolled inflammation including IL-6 release and ultimately resulting in a cytokine storm (Cao, 2020). Our data have demonstrated for the first time that, when given LCC, nasal *S. epidermidis* carries out fermentation to yield butyric acid as well as
Electrons. This electron production may facilitate bacterial nasal colonization, while the butyric acid can activate Ffar2 to down-regulate NPP-induced IL-6 production. These findings provide evidence that S. epidermidis colonization in the upper airway in humans can be considered the respiratory system’s first line of defence against SARS-CoV-2 infection.

**Experimental procedures**

**Ethics statement**

Mouse experiments were performed in accordance with a protocol (NCU-106-016, 19 December 2017) of the Institutional Animal Care and Use Committee (IACUC) of National Central University (NCU). Female ICR mice (8–9 weeks old) were obtained from the National Laboratory Animal Center Taipei, Taiwan. Mice were sacrificed by CO2 asphyxiation under isoflurane/sevoanaesthesia in an encased chamber.

**Sources of nasal swabs**

Nasal swabs were collected from a healthy human subject. Written consent was obtained from the participant prior to inclusion in the study. The Institutional Review Board (IRB) (No. 19-013-B1, 22 May 2019) at Landseed International Hospital, Taiwan, approved the consent procedure for nasal swab sampling.

**NPP cloning, expression and purification**

A plasmid carrying a gene encoding NPP (ID: YP_009724397.2) of SARS-CoV-2 was transformed into E. coli BL21 competent cells (Yeastern Biotech Co., Ltd, Taiwan). The E. coli BL21 transformed with a plasmid encoding GFP was used as a control. The E. coli BL21 was cultivated in 1 L Luria-Bertani (LB) broth (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) supplemented with 50 μg ml⁻¹ kanamycin at 37°C. At optical density OD₆₀₀nm = 0.6, 1 mM of IPTG was added into the culture of E. coli BL21 at 20°C for 16 h to induce protein expression. Proteins were purified by the ProBond™ Purification System (Invitrogen, Carlsbad, CA, USA) and visualized by Coomassie Brilliant Blue stained gels of 10% SDS-PAGE.

**Nasal inoculation and IL-6 detection**

Recombinant NPP (50 μg in 20 μl of PBS) was inoculated to the nasal cavities of ICR mice. Inoculation with the same amount of recombinant GFP served as a control. Six hours after inoculation, the tracheas in anesthetized mice were cannulated with a catheter. The BALF was obtained by lavaging the lungs 3 times each with 1-ml instillation (3 ml total) of PBS. The total lavage fluid from each mouse lung was pooled and centrifuged at 2000 rpm for 10 min. The level of IL-6 in the supernatant was quantified by ELISA using a Quantikine mouse IL-6 set (R&D Systems, Minneapolis, MN, USA). The level of IL-6 induced by NPP was normalized to that induced by GFP. Results were expressed as fold change over the GFP control.

**Bacterial electricity detection**

S. epidermidis ATCC 12228 was cultured in TSB (Sigma) at 37°C. The bacterial pellet was harvested by centrifugation at 15 000 g for 5 min, suspended in PBS. Electricity produced by S. epidermidis was measured by the changes in voltage (mV) against time (min) using a digital multimeter (Lutron, DM-9962SD, Sydney, Australia). Voltages were recorded every 5 s using a device equipped with a carbon felt (2.5 cm × 10 cm) and a carbon cloth (10 cm × 10 cm) (Homy Tech, Taoyuan, Taiwan) as anode and cathode respectively. The cathode was covered with a Nafion membrane N117 (6 cm × 6 cm) (Homy Tech) as a proton exchange membrane (PEM). Copper wires were used to link the anode and cathode to an external resistance (1000 Ω). S. epidermidis pretreated with or without 1 μM of roseoﬂavin (Sigma) for 24 h in the presence of LCC (TNJC corporation, Chiayi, Taiwan) was pipetted on the surface of the anode.

**Isolation of nasal septum and detection of butyric acid by HPLC**

Mouse nasal septum was isolated according to a protocol as previously described (Antunes et al., 2007). The isolated nasal septum with epithelium facing up was placed in 500 μl rich media [10 g l⁻¹ yeast extract (Biokar Diagnostics, Beauvais, France), 5 g l⁻¹ TSB, 2.5 g l⁻¹ K₂HPO₄ and 1.5 g l⁻¹ KH₂PO₄]. S. epidermidis ATCC 12228 (10⁸ CFU) in the absence or presence of 2% LCC was pipetted on the top of mouse nasal septum for 24 h. To detect butyric acid, media were collected and filtered through a 0.22 μm microfiltration membrane to remove bacteria and insoluble particles. One hundred microlitres of concentrated hydrochloric acid were added before samples were extracted for 20 min by gently rolling using 5 ml of diethyl ether. After centrifugation at 1100 g for 5 min, the supernatant was transferred to another Pyrex extraction tube before 500 μl of a 1-mM solution of NaOH was added. The aqueous phase was moved to an autosampler vial and 100 μl of concentrated hydrochloric acid were added. The analysis of butyric acid was conducted using an Agilent 1200 series HPLC system with a ZORBAX Eclipse XDB-C18 column (4.6 × 250 mm, 5 μm). The mobile phase was made up of 10% methanol/90% water (V/V) at a flow rate of 1 ml min⁻¹.
Colonization of S. epidermidis on mouse nasal cavities

To colonize S. epidermidis on mouse nasal cavities, ICR mice were intranasally inoculated 10^6 CFU/20 µl S. epidermidis every day. Three days after inoculation, nasal cavities were excised and homogenized in sterile PBS (0.1 g/100 µl). The CFUs of inoculated S. epidermidis on nasal cavities were enumerated by plating serial dilutions (1:10^0–1:10^5) of homogenates on a 500 µg ml^{-1} streptomycin-supplemented TSB agar plate at 37°C for 24 h. For some experiments, mouse nasal cavities without inoculation of S. epidermidis were homogenized and plated on streptomycin-supplemented TSB agar plates to count the endogenous bacteria on mouse nasal cavities. Sequence analysis of 16S ribosomal RNA (rRNA) genes was utilized for bacterial identification. A single colony of bacteria from a TSB agar plate was isolated with a sterile toothpick and boiled at 100°C for DNA extraction using an Easy Pure Genomic DNA Spin Kit (Bioman, New Taipei, Taiwan). Identification of S. epidermidis was confirmed by 16S rRNA sequencing using the 16S rRNA 27F and 534R primers for PCR (Wang et al., 2014). The 16S rRNA gene sequences were analyzed using the basic local alignment search tool (BLASTN, National Library of Medicine 8600 Rockville Pike, Bethesda, MD, USA).

Inoculation of NPP into S. epidermidis-colonized mice and inhibition of Ffar2

Mice colonized by S. epidermidis in nasal cavities were intranasally applied with 2% LCC or PBS 1 h before inoculation of recombinant NPP (50 µg in 20 µl PBS) for 6 h. The level of IL-6 in BALF was 84.84 ± 14.84 pg ml^{-1} 6 h after nasal inoculation of PBS. For Ffar2 inhibition, GLPG-0974, a Ffar2 antagonist (Tocris Bioscience, Bristol, UK), was dissolved in ethanol to make a stock solution. GLPG-0974 (1 mg kg^{-1} body weight) was diluted in saline and then was given at 1 ml kg^{-1} body weight every day by gastric gavage for 3 days before LCC inoculation. Ethanol (50% in saline) was used as a vehicle control. Six hours after inoculation of recombinant NPP, the level of IL-6 in BALF was measured by ELISA.

Statistical analysis

GraphPad Prism® software was applied for data analysis by unpaired t-test. The statistical significance was determined by P-values as follows: P-values of < 0.05 (*), < 0.01 (**), and < 0.001 (***)}. The mean ± standard deviation (SD) was calculated from results obtained from at least three separate experiments.

Limitations of the study

In this study, we have demonstrated that inoculation of LCC onto S. epidermidis-colonized nasal cavities mitigated SARS-CoV-2 NPP-induced IL-6 content in BALF in mice. Although data in vitro and ex vivo showed that LCC triggered S. epidermidis fermentation and produced butyric acid and electricity, further in-depth characterization of mechanism underlying the action of S. epidermidis fermentation to reduce IL-6 in vivo would be pertinent.

Resource availability

Lead contact

Further information and requests for resources should be directed to and will be fulfilled by the lead Contact, Huang Chun-Ming (chunming@ncu.edu.tw).

Materials availability

All unique/stable reagents generated in this study are available, on reasonable request, from the Lead Contact on a completed Materials Transfer Agreement.

Data and code availability

All data supporting the findings of this study are included in the article and its Supplemental Information or are available from the corresponding authors on request.

Acknowledgements

Support for the study was obtained from the Ministry of Science and Technology (MOST) Grants (108-2622-B-008-001-CC1; 108-2314-B-008-003-MY3, and 107-2923-B-008-008-003-MY3) and 106/107/108-Landseed Hospital-NCU joint grants. We especially thank Professor Ming-Fa Hsieh at the Department of Biomedical Engineering, Chung Yuan Christian University, Taoyuan, Taiwan, for providing HPLC to detect the butyric acid.

Conflict of interest

The authors declare that there no conflicts of interest.

Author contributions

Conceptualization: C.-M.H. Methodology and Investigation: M.-S.K., A.J.Y., J.J.Y., A.B. Resources: C.-M.H.
Writing-Original draft: C.-M.H., A.B., S.T., D.R.H. All authors read and provided input on the manuscript. Writing-Review and Editing: C.-M.H., M.-S.K., A.B., S.T., A.J.Y. J.J.Y. B.P.S. Supervision and Project Administration: C.-M.H. Funding Acquisition: C.-M.H.

References
Antunes, M.B., Woodworth, B.A., Bhargave, G., Xiong, G., Aguilar, J.L., Ratner, A.J., et al. (2007) Murine nasal septa for respiratory epithelial air-liquid interface cultures. *Biotechniques* 43: 195–196, 198, 200 passim.

Balasubramaniam, A., Adi, P., Do Thi, T.M., Yang, J.H., Labibah, A.S., and Huang, C.M. (2020) Skin bacteria mediate glycerol fermentation to produce electricity and resist UV-B. *Microorganisms* 8: 1092.

Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., et al. (2020) Remdesivir for the treatment of Covid-19 - preliminary report. *N Engl J Med* 383: 1813–1826.

Cao, X. (2020) COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol* 20: 269–270.

Chen, H.-W., Liu, P.-F., Liu, Y.-T., Kuo, S., Zhang, X.-Q., Schooley, R.T., et al. (2016) Nasal commensal *Staphylococcus epidermidis* counteracts influenza virus. *Sci Rep* 6: 27870.

Chen, Y.-W., Li, S.-W., Lin, C.-D., Huang, M.-Z., Lin, H.-J., Chin, C.-Y., et al. (2020) Fine particulate matter exposure alters pulmonary microbiota composition and aggravates pneumococcus-induced lung pathogenesis. *Front Cell Dev Biol* 8: 570484.

Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L.H., Huang, J., et al. (2021) The way of SARS-CoV-2 vaccine development: success and challenges. *Signal Transduct Target Ther* 6: 387.

Finke, N., Vandieken, V., and Jorgensen, B.B. (2007) Acetate, lactate, propionate, and isobutyrate as electron donors for iron and sulfate reduction in Arctic marine sediments, Svalbard. *FEMS Microbiol Ecol* 59: 10–22.

Fiune, M.M., Heldreth, B.A., Bergfeld, W.F., Belsito, D.V., Hill, R.A., Klaassen, C.D., et al. (2015) Safety assessment of alkyl esters as used in cosmetics. *Int J Toxicol* 34: 55–69S.

Gallo, O., Locatello, L.G., Mazzoni, A., Novelli, L., and Annunziato, F. (2021) The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. *Mucosal Immunol* 14: 305–316.

Gilzad-Kohan, H., and Jamali, F. (2020) Anti-inflammatory properties of drugs used to control COVID-19 and their effects on the renin-angiotensin system and angiotensin-converting enzyme-2. *J Pharm Pharm Sci* 23: 259–277.

Gomez-Carretero, S., Libberton, B., Svennersten, K., Person, K., Jager, E., Berggren, M., et al. (2017) Redox-active conducting polymers modulate Salmonella biofilm formation by controlling availability of electron acceptors. *NPJ Biofilms Microbiomes* 3: 19.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y.I., et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395: 497–506.

Huang, W., Man, Y., Gao, C., Zhou, L., Gu, J., Xu, H., et al. (2020) Short-chain fatty acids ameliorate diabetic nephropathy via GPR43-mediated inhibition of oxidative stress and NF-kappaB signaling. *Oxid Med Cell Longev* 2020: 4074832.

Huang, W.C., Tsai, T.H., Chuang, L.T., Li, Y.Y., Zouboulis, C.C., and Tsai, P.J. (2014) Anti-bacterial and anti-inflammatory properties of capric acid against Propionibacterium acne: a comparative study with lauric acid. *J Dermatol Sci* 73: 232–240.

Ji, J.Y., Chung, J.H., Kim, N.S., Seo, Y.H., Jung, H.S., Chun, H.R., et al. (2021) The nasal symbiont *Staphylococcus epidermidis* shapes the cellular environment to decrease expression of SARS-CoV-2 entry factors in nasal epithelium. *iScience* 24: 103172.

Kao, M.S., Huang, S., Chang, W.L., Hsieh, M.F., Huang, C.J., Gallo, R.L., and Huang, C.M. (2017) Microbiome precision editing: using PEG as a selective fermentation initiator against methicillin-resistant *Staphylococcus aureus*. *Biotechnol J* 12.

Keshari, S., Balasubramaniam, A., Myagmardoloonjin, B., Herr, D.R., Negari, I.P., and Huang, C.M. (2019) Butyric acid from probiotic *Staphylococcus epidermidis* in the skin microbiome down-regulates the ultraviolet-induced pro-inflammatory IL-6 cytokine via short-chain fatty acid receptor. *Int J Mol Sci* 20: 4477.

Keshari, S., Wang, Y., Herr, D.R., Wang, S.-M., Yang, W.-C., Chuang, T.-H., et al. (2020) Skin cutibacterium acne mediates fermentation to suppress the calcium phosphate-induced itching: a butyric acid derivative with potential for uremic pruritus. *J Clin Med* 9: 312.

Kim, H.J., Jo, A., Jeon, Y.J., An, S., Lee, K.M., Yoon, S.S., and Choi, J.Y. (2019) Nasal commensal *Staphylococcus epidermidis* enhances interferon-lambda-dependent immunity against influenza virus. *Microbiome* 7: 80.

Lee, E.R., Blount, K.F., and Breaker, R.R. (2009) Roseoflavin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression. *RNA Biol* 6: 187–194.

Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuin, J., et al. (2021) Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. *Nat Med* 2: 2108–2110.

Light, S.H., Su, L., Rivera-Lugo, R., Cornejo, J.A., Louie, A., lavarone, A.T., et al. (2018) A flavin-based extracellular electron transfer mechanism in diverse Gram-positive bacteria. *Nature* 562: 140–144.

Liu, J., Chang, G., Huang, J., Wang, Y., Ma, N., Roy, A.C., and Shen, X. (2019) Sodium butyrate inhibits the inflammation of lipopolysaccharide-induced acute lung injury in mice by regulating the toll-like receptor 4/nuclear Factor kappaB signaling pathway. *J Agric Food Chem* 67: 1674–1682.

Lu, J., Peng, J., Xiong, Q., Liu, Z., Lin, H., Tan, X., et al. (2020) Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR. *EBioMedicine* 59: 102960.

Luo, Q., Wang, H., Zhang, X., and Qian, Y. (2005) Effect of direct electric current on the cell surface properties of phenol-degrading bacteria. *Appl Environ Microbiol* 71: 429–427.
MacLea, K.S., and Trachtenberg, A.M. (2017) Complete genome sequence of *Staphylococcus epidermidis* ATCC 12228 chromosome and plasmids, generated by long-read sequencing. *Genome Announc* 5: e00954-17.

Mansjo, M., and Johansson, J. (2011) The riboflavin analog roseo flavin targets an FMN-riboswitch and blocks Listeria monocytogenes growth, but also stimulates virulence gene-expression and infection. *RNA Biol* 8: 674–680.

Marsili, E., Baron, D.B., Shikhare, I.D., Coursolle, D., Gralnick, J.A., and Bond, D.R. (2008) Shawenella secretes flavins that mediate extracellular electron transfer. *Proc Natl Acad Sci USA* 105: 3968–3973.

McGonagle, D., Sharif, K., O'Regan, A., and Bridgewood, C. (2020) The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. *Autoimmun Rev* 19: 102537.

Miroux, B., and Walker, J.E. (1996) Over-production of proteins in *Escherichia coli* mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. *J Mol Biol* 260: 289–298.

Moore, S.A., Faulkner, G., Rhodes, R.E., Brussoni, M., Chulak-Bozzer, T., *et al.* (2020) Impact of the COVID-19 virus outbreak on movement and play behaviours of Canadian children and youth: A national survey. *Int J Behav Nutr Phys Act* 17: 85. https://doi.org/10.1186/s12966-020-00987-8

Mornioli, D., Gianni, M.L., Consales, A., Pietrasanta, C., and Mosca, F. (2020) Human sialome and coronavirus disease-2019 (COVID-19) pandemic: an understated correlation? *Front Immunol* 11: 1480.

Namour, F., Galien, R., Van Kaem, T., Van der Aa, A., Vanhoutte, F., Beetens, J., and Van’t Klooster, G. (2016) Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects. *Br J Clin Pharmacol* 82: 139–148.

Nardelli, C., Gentile, I., Setaro, M., Di Domenico, C., Pinchera, B., Buonomo, A.R., *et al.* (2021) Nasopharyngeal microbiome signature in COVID-19 positive patients: Can We definitively get a role to fusobacterium periodonticum? *Frontiers in Cellular and Infection Microbiology* 11. https://doi.org/10.3389/fcimb.2021.625581

Patil, S.A., Hägerhäll, C., and Gorton, L. (2012) Electron transfer mechanisms between microorganisms and electrodes in bioelectrochemical systems. *Bioart Rev* 4: 159–192.

Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y.U., *et al.* (2020) Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 71: 762–768.

Sacco, N.J., Bonetto, M.C., and Corton, E. (2017) Isolation and characterization of a novel electrogenic bacterium, *Dietzia* sp. RNIV-4. *PLoS One* 12: e0169935.

Sarjit, A., Tan, S.M., and Dykes, G.A. (2015) Surface modification of materials to encourage beneficial biofilm formation. *AIMS Bieng* 2: 404–422.

Sebastian, M., Arilla-Luna, S., Bellalou, J., Yruela, I., and Medina, M. (2019) The biosynthesis of flavin cofactors in *Listeria monocytogenes*. *J Mol Biol* 431: 2762–2776.

Sohn, M., Amoros-Galicia, L., Krus, S., Martin, K., and Herzog, B. (2020) Effect of emollients on UV filter absorbance and sunscreen efficiency. *J Photochem Photobiol B* 205: 111818.

S. epidermidis mitigates SARS-CoV-2-induced IL-6 1993

Solis-Garcia Del Pozo, J., Galindo, M.F., Nava, E., and Jordan, J. (2020) A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients. *Eur Rev Med Pharmacol Sci* 24: 7475–7484.

dan, J. (2020) A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients. *Eur Rev Med Pharmacol Sci* 24: 7475–7484.

van der Stel, A.X., Boogerd, F.C., Huynh, S., Parker, C.T., van Dijk, L., van Putten, J.P.M., and Woesten, M. (2017) Generation of the membrane potential and its impact on the motility, ATP production and growth in *Campylobacter jejuni*. *Mol Microbiol* 105: 637–651.

Tan, M., Liu, Y., Zhou, R., Deng, X., Li, F., Liang, K., and Shi, Y. (2020) Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. *Immunology* 160: 261–268.

Tang, Y., Liu, J., Zhang, D., Xu, Z., Ji, J., and Wen, C. (2020) Cytokine storm in COVID-19: the current evidence and treatment strategies. *Front Immunol* 11: 1708.

Tomazine, B.M., Maia, I.S., Bueno, F.R., Silva, M.V.A.O., Baldassare, F.P., Costa, E.L.V., *et al.* (2020) COVID-19-associated ARDS treated with DEXamethasone (CoDEX): Study design and rationale for a randomized trial. *medRxiv* https://doi.org/10.1101/2020.06.24.20139303.

Traisaeng, S., Herr, D.R., Kao, H.J., Chuang, T.H., and Huang, C.M. (2019) A derivative of butyric acid, the fermentation metabolite of *Staphylococcus epidermidis*, inhibits the growth of a *Staphylococcus aureus* strain isolated from atopic dermatitis patients. *Toxins (Basel)* 11: 311.

Wang, G., Jiang, L.I., Wang, J., Zhang, J., Kong, F., Li, Q., *et al.* (2020) The G protein-coupled receptor FFAR2 promotes internalization during influenza A virus entry. *J Virol* 94: e01707-19.

Wang, W., Ye, L., Ye, L., Li, B., Gao, B., Zeng, Y., *et al.* (2007) Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway. *Virus Res* 128: 1–8.

Wang, Y., Kuo, S., Shu, M., Yu, J., Huang, S., Dai, A., *et al.* (2014) *Staphylococcus epidermidis* in the human skin microbiome mediates fermentation to inhibit the growth of Propionibacterium acnes: implications of probiotics in acne vulgaris. *Appl Microbiol Biotechnol* 98: 411–424.

Zhang, X., Wu, K., Wang, D., Yue, X., Song, D., Zhu, Y., and Wu, J. (2007) Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB. *Virology* 365: 324–335.

Zhang, X., Xue, C., Xu, Q., Zhang, Y., Li, H., Li, F., *et al.* (2019) Caprylic acid suppresses inflammation via TLR4/NF-kappaB signaling and improves atherosclerosis in ApoE-deficient mice. *Nutr Metab (Lond)* 16: 40.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** Nasal colonization of inoculated *S. epidermidis* was verified by 16S rRNA gene sequencing (A) *S. epidermidis* bacteria (ATCC 12228) (*S. epil*) (16S CFU) or nasal homogenates (0.2 g) (NH) of ICR mice were serially diluted (1:10−, 1:10^2) and placed on a 500 μg/mL streptomycin supplemented TSB agar plate at 37°C for 24 h. *S. epidermidis*, but...
not endogenous bacteria in nasal cavities, can grow on streptomycin supplemented TSB agar plates. (B) ICR mice were intranasally inoculated 10⁸ CFU/20 μL S. epidermidis every day for 3 days. Nasal homogenates (0.1 g/100 μL) were placed on a streptomycin supplemented TSB agar plate for 24 h. One of colonies (arrow) were selected for bacterial identification by 16S rRNA gene sequencing. (C) The nucleotide sequence of 16S rRNA gene of the selected colony shared 99% identity to S. epidermidis CLC-M16.

Fig. S2. Nasal administration of LCC did not affect the NPP-induced IL-6. LCC (+LCC) or PBS (-LCC) was administered to the nasal cavities of ICR mice 6 h before subsequent inoculation of recombinant NPP. The level of IL-6 in BALF was measured by ELISA 6 h after NPP inoculation. The level of IL-6 induced by LCC relative to that induced by PBS was expressed as fold change. Data are represented as mean ± SD, in triplicate, two-tailed t-tests. ns = non-significant.

Fig. S3. Treatment of mouse macrophage J774A.1 cells with recombinant NPP induced a higher IL-6 level compared to treatment of cells with recombinant GFP. The NPP-induced IL-6 was reduced by pre-treatment of cells with butyric acid. The reduction was partially restored by treatment of GLPG-0974, a Ffar2 antagonist. ELISA was used to quantify IL-6. Data represented as mean ± SD, in triplicate, two-tailed t-tests. P-values of <0.001 (***).

Fig. S4. A S. epidermidis strain isolated from human nasal cavities fermented LCC and produced electricity (A) A S. epidermidis K1 strain (10⁷ CFU) isolated from human nasal cavities (Table S1) was incubated in rich media (M) with/without LCC for 12 h. Rich media alone and rich media plus LCC without S. epidermidis were included as controls. The pH values of media 12 h after fermentation were indicated. The color of phenol red in rich media changed from red-orange to yellow and reduction of pH values were used as indicators of bacterial fermentation. (B) The S. epidermidis K1 strain (10⁷ CFU) with/without 2% LCC in rich media was pipetted on an anode. Pipetting media alone (M) or LCC alone acted as a control. The voltage difference (mV) between anode and cathode was monitored for 20 min.

Fig. S5. The expression levels of genes (pdh and ndh2) in the S. epidermidis ATCC 12228 and K1 strains. RT-qPCR was used to examine the relative expression of the pdh and ndh2 genes which were normalized to 16S rRNA gene. Data shown represent the mean ± SD of experiments performed in triplicate, two-tailed t-tests. P-values of <0.001 (***).

Table S1. 16S rRNA gene sequences of 11 bacterial colonies (K1, K2, H1, H2, and 1-7) isolated from human nasal cavities.

Table S2. The designed primers for EET related genes.